AKT1 and ovarian cancer: The drug combination SUNITINIB and LAPATINIB acted synergistically against the human ovarian cancer cell line SKOV3, modulating the PI3K/AKT/mTOR pathway corresponding to SUNITINIB and inhibiting HER2 target proteins corresponding to LAPATINIB, which inhibited SKOV3 cell proliferation and tumor growth (Komarova et al. 2011, Yang et al. 2017).